Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.69 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9781838 | 0.95 | L3MBTL1 (0.65) | L3MBTL1ALOX5SMN1; SMN2LTA4HCYP4F2 | |
| SCHEMBL9781776 | 0.86 | L3MBTL1 (0.78) | L3MBTL1 | |
| SCHEMBL8899583 | 0.85 | L3MBTL1 (0.76) | L3MBTL1 | |
| SCHEMBL9434778 | 0.83 | L3MBTL1 (0.78) | L3MBTL1 | |
| SCHEMBL9434959 | 0.83 | L3MBTL1 (0.78) | L3MBTL1 | |
| SCHEMBL6629239 | 0.83 | L3MBTL1 (0.73) | L3MBTL1 | |
| SCHEMBL8863680 | 0.82 | L3MBTL1 (0.76) | L3MBTL1 | |
| SCHEMBL6441659 | 0.82 | L3MBTL1 (0.62) | L3MBTL1ALOX5TDP1LTA4H | |
| SCHEMBL9326780 | 0.81 | L3MBTL1 (0.64) | L3MBTL1 | |
| SCHEMBL9327971 | 0.81 | L3MBTL1 (0.64) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369848-A1 | Conjugation Method for Carrier-Linked Prodrugs | Ascendls Pharma A/S (DK) | 2021-12-02 | — | — | US | disclosed |
| WO-2018011266-A1 | CONJUGATION METHOD FOR CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369848-A1 | Conjugation Method for Carrier-Linked Prodrugs | UGT2B7, SLC10A1, UGT1A6 | L3MBTL1 2842/4885ALOX5 893/4885ALDH1A1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.